Rate Video

EHA 2020 | SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML

Christoph Röllig • 26 Jun 2020

Acute Myeloid Leukemia Leukemia Daunorubicin

SAL-DaunoDouble

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results from the SAL-DaunoDouble trial comparing 90 mg versus 60 mg in a standard 7+3 induction regimen for newly diagnosed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

AML: new targeted inhibitors as single agents?

Christoph Röllig • 26 Jun 2020

Single versus double induction with 7+3 for newly diagnosed AML

Christoph Röllig • 8 Dec 2020

MRD Focus: why measurable residual disease testing is the future

Bruno Paiva et al.

Clinical advances in acute myeloid leukemia

Christoph Röllig • 25 Feb 2016

Related Videos

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021